Educational only — this site does not provide personalised medical advice. Read the full disclaimer.
The Longevity Review Without the sales pitch
Emerging

Multi-Cancer Early Detection Blood Tests

Last reviewed 25 August 2026 · Evidence-graded review — see Methodology

A single blood draw claiming to detect dozens of cancers by reading fragments of tumour DNA shed into the bloodstream, sold in Singapore under several brand names at four figures. The technology is real and the validation work is serious. What does not yet exist is evidence that taking the test makes anyone live longer.

Why it grades Emerging

Klein EA, Richards D, et al. “Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set of asymptomatic and symptomatic individuals.” Ann Oncol 2021;32:1167–1177 reported high specificity alongside sensitivity that varies enormously by cancer type and stage — lowest in early-stage disease, which is precisely where a screening test has to work. The randomised trial built to answer the mortality question, NHS-Galleri, is described in Neal RD, et al. Cancers 2022;14:4818. Until it reports, this is a test bought on plausibility.

Klein EA, et al. Ann Oncol. 2021. PubMed: PMID 34176681 · Neal RD, et al. Cancers. 2022. PubMed: PMID 36230741

Frequently sold alongside — and sometimes implicitly instead of — the conventional screening on this page. A negative result does not mean you can skip FIT or mammography, both of which have been shown to reduce mortality.
FrequencyNot established
Cost (SGD)S$1,200–2,500
Appropriate forNobody, as a substitute for guideline screening. A positive result triggers a whole-body diagnostic work-up with no guarantee of finding anything

Singapore guidance

Not covered in the current review

Singapore’s national screening committee has not reviewed this test in the current volume of its report, which covers nine conditions. That is not a verdict either way.

Source: Screening Test Review Committee report 2026, Volume 1 (Academy of Medicine Singapore and Ministry of Health, February 2026). The full national list · How this is used.

What you would actually pay

Healthier SG
Not subsidised
MediSave
Not among the screenings named for outpatient claims

Source: Healthier SG Screening (HealthHub) and MediSave outpatient care (Ministry of Health). Absence from either list is not a statement that the test is discouraged — only that no subsidy or claim applies. Gross prices compared.

What it costs when it is wrong

Basis
No published harm criterion found
Severity
Not documented

Not covered in the current volume of the committee’s report, so no harm criterion was found either way.

An empty finding, not a clean bill of health: this means nothing documented was found for this test. It is not a claim that the test is safe.

Screening harm is not only a laboratory question: the committee’s own criteria advise against a test when “the screening test, or follow-up tests arising from a positive screen, are associated with significant medical risks”. Sources on overdiagnosis → · How this is graded.

FAQ

Is the Multi-Cancer Early Detection Blood Tests worth doing in Singapore?

Judged for screening an asymptomatic adult, Multi-Cancer Early Detection Blood Tests grades emerging on our rubric. It is most appropriate for nobody, as a substitute for guideline screening. A positive result triggers a whole-body diagnostic work-up with no guarantee of finding anything. It typically costs S$1,200–2,500 in Singapore. It is not established.

Weighing this against something else? Compare it with two other tests → · Price it inside a panel →